Starna Therapeutics, a pioneering biotechnology company developing next-generation RNA and in vivo CAR-T therapies, today announced the successful closing of its Series B financing round exceeding RMB 300 million. The round was led by LYFE Capital, Hillhouse Ventures, and LAV, with continued participation from existing investors, underscoring strong confidence in Starna’s scientific leadership and clinical vision.

The new funds will be used to expand Starna’s proprietary extrahepatic delivery platform and accelerate the clinical development of its in vivo CAR-T pipeline, a breakthrough approach that enables direct reprogramming of immune cells within the body. The investment will also support continued innovation in RNA therapeutics and manufacturing capabilities to drive global competitiveness in cell and gene therapy.

Starna’s extrahepatic delivery platform enables precise, tissue-targeted delivery of RNA payloads beyond the liver, addressing a major limitation in current RNA and gene-editing technologies. Its in vivo CAR-T candidates are designed to reprogramme T cells directly inside the patient’s body, offering simplified manufacturing, reduced costs, and faster turnaround compared to conventional CAR-T therapies.

The Series B financing follows a series of recent scientific milestones for Starna, including promising preclinical data demonstrating robust efficacy and safety of its lead in vivo CAR-T candidates. The company continues to strengthen collaborations with leading research institutions and aims to advance multiple candidates into clinical development in 2026.

With this latest funding, Starna Therapeutics reinforces its commitment to transforming the future of RNA and cellular therapies, advancing precision medicine solutions that are both scalable and accessible.